Surveillance of meningococcal infections in Belgium  by Looveren, Marleen Van et al.
2 2 4  C l i n i c a l  M i c r o b i o l o g y  a n d  Infection, Volume 4 Number 4, A p r i l  1998 
the patient was initially treated for toxoplasmosis based 
on serologic data. During the second toxoplasrmc 
episode, it is unclear whether toxoplasmic reactivation 
was initiated by the surgical procedure or had already 
started before surgery. The patient was receiving broad- 
spectrum antibacterial therapy at the time of sampling 
of the peritoneal fluid. Therefore, negative culture for 
bacteria cannot rule out the possibility of a bacterial 
peritonitis, although the cell count of the peritoneal 
fluid makes this hypothesis unlikely. Whilst detection 
of DNA by PCR is not absolute evidence for the 
presence of viable 7: gondii, rapid clinical improvement 
with resolution of the fever after institution of specific 
antiprotozoal therapy supports the diagnosis of active 
toxoplasmosis. The fact that the patient was treated 
with pyrimethamine at the time of reactivation 
confirms previous reports that pyrimethamine alone 
is not always efficient in preventing toxoplasmosis 
in immunocompromised patients [6],  and further 
emphasizes the importance of DNA amplification, 
since diagnosis of toxoplasmosis is unlikely to be 
established by mice inoculation or cell culture in a 
patient receiving antiprotozoal therapy. 
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Surveillance of meningococcal infections in Belgium 
Clin Microbiol Infect 1998; 4: 224-228 
Meningococcal hsease remains an important public- 
health problem in both developing [l] and industrial- 
ized countries [2]. Before 1990, the annual incidence 
of meningococcal dlsease in Belgium fluctuated around 
one case per 100000 inhabitants. However, since the 
early 1990s an increase in the incidence of meningo- 
coccal hsease has been seen. 
Meningococci are subdivided into serotypes based 
on the immunologic properties of several outer- 
membrane proteins and lipopolysaccharides (31, and 
development of monoclonal antibodies against those 
antigens has significantly contributed to a better under- 
standing of the epidemiology of meningococcal disease 
In Belgium, serogroup B is the predominant sero- 
group causing meningococcal dlsease, followed by 
serogroup C. No effective vaccine is currently avail- 
able for protection against group B meningococcal 
disease, because the B capsular polysaccharide is not 
immunogenic in humans [4]. The recent emergence of 
penicillin-resistant meningococcal strains [5,6] may 
create additional therapeutic problems. 
In the present investigation we describe the 
spread in Belgium of a serogroup B strain which 
was first reported in The Netherlands in the early 
1980s [7]. Isolates were characterized by traditional 
serotyping, and their susceptibility patterns to a panel 
of antimicrobial agents were determined. Extensive 
phenotyping (multilocus enzyme electrophoresis) and 
genotyping (PCR and pulsed-field gel electrophoresis 
analyses) were performed on these and other strains [8] .  
Meningococcal infections are notifiable in Belgium. 
Trends of meningococcal disease have been derived 
from epidemiologic and laboratory data sets that are 
complementary but are maintained separately. On the 
one hand, the Federal Belgian Health Inspection 
receives physician notifications; data include age, 
gender, date and location. On the other hand, the 
Belgian Meningococcal Reference Center at the 
Scientific Institute for Public Health-Louis Pasteur 
(Brussels) receives isolates of Neisseria meningitidis horn 
[31. 
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the Belgian &agnostic laboratories for confirmation 
and determination of serotype, subtype, and suscepti- 
bility pattern. Since 1985, the annual number of 
meningococcal isolates submitted to the Belgian 
Meningococcal Reference Center has exceeded the 
number of cases reported [9]. It is generally accepted 
that the number of submissions to the Belgian Meningo- 
coccal Reference Center is hghly representative for the 
number of cases of meningococcal disease in Belgium. 
From 1990 to 1995, isolates from 769 patients 
(429 males, 324 females, 16 of unspecified gender; 
nlale/female ratio 1.32) were submitted to the Belgian 
Meningococcal Reference Center. Seven hundred and 
fifty-three strains were recovered from cerebrospinal 
fluid or blood, and 16 strains were throat or skin isolates 
of patients with meningococcal disease. 
Serogroups were determined by slide agglutination 
with commercially available rabbit antisera specific 
for the A, C, X, Y, Z ,  W135 (Murex Diagnostics, 
Dartford, UK) and 29E (Diagnostics Pasteur, Marnes- 
la-Coquette, France) capsular polysaccharides [lo]. 
For serogroup B, a monoclonal antibody (Murex 
Diagnostics, Dartford, UK) was used. 
Serotyping and subtyping with monoclonal anti- 
bodies U.T. Poolman, National Institute of Public 
Health and Environmental Protection, Bilthoven, The 
Netherlands) was carried out using an enzyme-linked 
immunoblot assay [ l l ]  or whole cell ELISA [12]. 
In Belgium, an epidemic elevation of the number 
of cases of meningococcal disease was observed 
between 1969 and 1975. In 1972, the epidemic reached 
its peak incidence of 5.3 cases per 100 000 inhabitants 
[13]. Afterwards, the incidence of disease decreased and 
fell to normal inter-epidemic proportions of one case 
per 100000 inhabitants per year. Except for a small 
augmentation in 1980, the incidence has fluctuated 
around this value. However, during the past 6 years, 
the incidence of meningococcal disease in Belgium, 
calculated from the submission of meningococcal 
isolates to the Belgian Meningococcal Reference 
Center, has gradually increased from 0.8 cases per 
100 000 inhabitants in 1990 to 2.0 cases per 100 000 
inhabitants in 1995. This increase is particularly due 
to a rise in the proportion of serogroup B strains. 
Serogroup B meningococci always accounted for more 
than 60% of the cases of meningococcal disease, but 
in recent years their proportion has increased to up to 
80% of the cases. The distribution of serotypes and 
subtypes of all 568 serogroup B isolates obtained during 
1990-95 is shown in Table 1. Amongst the serogroup 
B strains, the increase of serotype 4 isolates was the most 
obvious, their relative frequency increasing from 4% in 
1990 to 74% in 1995. Serotype 4 strains were mostly 
associated with subtype P1.4 group B isolates. The 
proportion of subtype P1.4 increased from 6% in 1990 
to 48% in 1995 (Table 1). Strains with phenotype 
B:4:P1.4 currently cause 32.5% of the cases of meningo- 
coccal disease; however, B:non-typeable:P1.4 strains 
account for an additional 3.5% (total of 36.0%)). 
Strains with phenotype B:4:P1.4 were first isolated 
in The Netherlands in 1980 [7]. Until 1984, they were 
predominantly recovered in the southwestern part of 
The Netherlands in the vicinity of Rotterdam and 
Breda. Thereafter, the phenotype dispersed throughout 
the country, but the incidence remained most pro- 
nounced in the southern provinces [14]. In Belgium, 
an increase of meningococcal infections, with B:4:P1.4 
and B:non-typeable:P1.4 as predominant phenotypes, 
was first noticed in the province of Antwerp, near the 
border with The Netherlands. Later, a similar trend 
was seen in other provinces of Belgium, particularly 
East and West Flanders. In 1994, the Walloon provinces 
were reached, and in 1995 phenotypes B:4:P1.4 and 
B:non-typeable:P1.4 were encountered in all Belgian 
provinces (Figure 1). Consequently, dispersion of the 
Dutch B:4:P1.4 strain in Belgium can be hypothesized. 
Table 1 Distribution of serotypes and subtypes among 568 
serogroup B meningococci isolated f?om patients with 
meningococcal dsease in Belgium between 1990 and 1995 
Year of isolation 
1990 1991 1992 1993 1994 1995 
No ofisolates tested 53 77 91 94 95 158 
Serotypes (%) 
1 
2a 
2b 
4 
14 
15 
16 
Non-serotypeable 
Subtypes (%) 
P1.l 
P1.1,'7 
P1.2 
P1.2,5 
P1.4 
P1.5 
P1.6 
P1.7 
P1.7,16 
P1.9 
P1.10 
P1.1:? 
P1.13 
P1.M 
Pl.15 
P1.16 
Non-subtypeable 
- 3 2 6 2 4  
4 3 2 1 1 1  
6 3 4 4 5 -  
4 1 7 38 53 74 
2 - 2 2 - 1  
9 1 0  7 9 4 5  
- 4 3 -  - -  
75 77 74 40 34 14 
- 6 1 -  - -  
- - 3 2 8 4  
1 3 1 0  3 4 3 1 
- 4  
6 21 32 40 45 48 
- - - 2 - 3  
9 -  - 1 - 2  
- 1 - 3 2 3  
- - 3 6 4 4  
2 4 2 - 3 1  
2 1 10 11 11 - 
- - 2 4 - 2  
- - - 9 8 9  
- 1 3 1 5  
9 2 6  7 3 4 6  
8 1 0  5 3  1 4  
51 19 30 7 8 4 
- - - -  
- 
2 2 6  C l i n i c a l  M i c r o b i o l o g y  a n d  I n f e c t i o n ,  V o l u m e  4 N u m b e r  4 ,  A p r i l  1 9 9 8  
N/  100 000 inhabitants 
0.5<NI 1 
Figure 1 Evolution of the geographic mstribution of isolates belonging to the phenotypes B:4:P1.4 or B:non-typeable: P1.4 
in the period 1990-95. The incidence rate per 100 000 of inhabitants is given. 
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These and other [8] data suggest that the ele- 
vated number of meningococcal infections is due to 
the introduction of a new strain of A! meningitidis 
@:4:P1.4/B:non-typeable:P1.4) in Belgium since the 
beginning of the 1990s. The introduction of a new 
strain in a susceptible population was previously shown 
to cause a rise in the number of meningococcal 
infections [7]. In The Netherlands, the incidence of 
serotype B:4 rose from 11% in 1980 to 43% in 1990, 
and the incidence of the subtype P1.4 increased from 
3% in 1980 to 41% in 1990 [7]. However, the highest 
prevalence of strain B:4:P1.4 was only 21%. As a 
consequence, B:4:P1.4 alone could not be held respon- 
sible for the increase of meningococcal disease in The 
Netherlands after 1982 [7]. Also in England and Wales, 
B:4:P1.4 strains have become established in the past 5 
years and now account for a quarter of all group B 
infections (25% in 1995) [15]. 
Age distribution 
Meningococcal disease predominates in the age group 
of 0-4 years, accounting for 38-49% of the annual 
registered number ofcases. From 1990 to 1995, children 
less than 1 year of age accounted for 13.0%, 17.7%, 
15.1%, 18.1%, 17.3%, and 12.5%, respectively, of the 
cases of meningococcal disease. However, from 1993 
onwards, a secondary peak was observed in the age 
group &om 15 to 19 years. The incidence among 
children aged between 15 and 19 years old increased 
fi-om 0.9 per 100000 inhabitants in 1991 (95% con- 
fidence interval (95% CI): 0.2-1.7) to 6.2 per 100 000 
inhabitants in 1995 (95% CI: 4.2-8.2). This difference 
of 5.3 was statistically significant (95% CI: 3.2-7.4). A 
shift in age distribution &om younger to older age 
categories has been observed before and was explained 
by a coinciding shift of the serogroup and/or sero- 
subtype distribution [7]. Indeed, in Belgium, serogroup 
B has become more prevalent in recent years, and the 
introduction of phenotypes not previously encountered 
has also been seen (B:4:P1.4 and B:non-typeable:P1.4). 
Antibiotic susceptibility testing 
A random sample of 420 clinical isolates stratified 
by serogroup and year of isolation was selected for 
susceptibility testing by E-test (AB Biodisk, Solna, 
Sweden). The use of the E-test for determining anti- 
biotic susceptibility of N. meningitidis was validated by 
Hughes et al [16]. They found that E-test MICs were 
within rf: 1 log2 dilution of the MICs by agar dilution. 
The susceptibdities to five antimicrobial agents, 
i.e. penicillin, rifampicin, sulfadiazine, ciprofloxacin 
and ceftriaxone, were determined. The E-test was 
performed as previously described by Blondeau and 
Yaschuk [17]. Definitions of susceptibility were as 
follows: for penicillin, MIC 5 0.06 mg/L indcated 
susceptibility, MIC >0.06-1 mg/L relative resistance, 
and MIC >l mg/L resistance [6]; for all other 
antimicrobial agents, published NCCLS breakpoint 
definitions were used [18]. 
Although penicillin remains the drug of choice for 
serious meningococcal disease, the drug appears to be 
less active because of emerging resistance [17,19-211, 
The first meningococcal strain isolated in Belgium 
with a reduced susceptibility to penicillin (0.5 mg/L) 
was reported in 1993 [22]. We observed a reduced 
susceptibility to penicdhn (MIC > 0.06-0.125 mg/L) 
[16,17] for 27 strains (6.4%). The strains showed 
the following MICs: 0.064 mg/L for 18 isolates, 
0.094 mg/L for eight isolates and 0.125 mg/L for 
one isolate. High-level resistance to sulfadiazine (MIC 
>256mg/L) was observed in 80 strains (19.0%). No 
association was found between sulfadiazine resistance 
and serotype or subtype. All 420 isolates were suscep- 
tible to rifampicin, ciprofloxacin and cefiriaxone. 
In conclusion, we hypothesize that the increase in 
the incidence of meningococcal disease in Belgium is 
due to the introduction of a new strain of N. meningitidis 
(B:4:P1,4) in the susceptible Belgian population since 
the early 1990s. Phenotype B:4:P1.4 strains were first 
encountered in The Netherlands, and have caused 
disease their since the early 1980s. We suggest that these 
strains dispersed into Belgium fi-om 1990 onwards. 
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First case of Salmonella hirschfeldii (paratyphi C) 
infection of a prosthetic hip 
Clin Microbiol Infect 1998; 4: 228-230 
Infection after a total hip replacement is a serious 
complication, ohen requiring removal of the prosthesis 
for healing [l]. The commonest etiologic agents are 
Staphylococcus aureus and Staphylococcus epidermidis, which 
account for more than 50% of the pathogens isolated, 
according to recent series. Other organisms may be 
involved, especially in hematogenous infections, in- 
cluding Gram-negative bacteria, Streptococcus, anaerobic 
bacteria, chphtheroids, or mycobacteria [1,2]. We report 
the first case of typhoid salmonella infection of a total 
hip prosthesis. 
A 51-year-old black African man was admitted 
because of fever, pain of the right hip and a fistula from 
the joint to the thigh surface. His past medical history 
was remarkable for several episodes of malaria, and type 
2 diabetes meultus. Eleven years before this admission, 
he suffered post-traumatic necrosis of the right femoral 
head, and underwent total hip arthroplasty with a 
satisfactory postsurgical functional result. Thirty months 
before admission, the patient suddenly developed a 
fever, and swelling of the upper lateral part of the 
right thigh. A hlp puncture, performed in Brazzaville, 
